Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1

Shuqin Wang, Xue Li, Weizhe Xu, Jing Gao, Yin Wang, Xiaoyuan Jia, Gongchu Li, Qiuwei Pan, Kan Chen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
22 Downloads (Pure)

Abstract

Nonalcoholic fatty liver disease (NAFLD) is recognized as a metabolic disease characterized by hepatic steatosis. Despite the growing burden of NAFLD, approved pharmacological treatment is lacking. As an inhibitor of androgen receptor (AR), EPI-001 is being explored for the treatment of prostate cancer. This study aimed to investigate the potential of EPI-001 for treating NAFLD in free fatty acids (FFAs)-induced human hepatic cells and high-fat-high-sugar (HFHS)-feeding mice. Our results showed that EPI-001 reduced lipid accumulation in hepatic cells and ameliorated hepatic steatosis in mouse livers. Further exploration suggested that the effect of EPI-001 was associated with CYP2E1-mediated reduction of reactive oxygen species (ROS). This provides encouraging evidence for further studies on EPI-001 therapy for NAFLD.

Original languageEnglish
Article number16063
JournalInternational Journal of Molecular Sciences
Volume23
Issue number24
DOIs
Publication statusPublished - 16 Dec 2022

Bibliographical note

Funding Information:
This work was supported by the National Natural Science Foundation of China (No. 81972281), and Natural Science Foundation of Zhejiang Province (No. LGF22C010005).

Publisher Copyright:
© 2022 by the authors.

Fingerprint

Dive into the research topics of 'Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1'. Together they form a unique fingerprint.

Cite this